Cellular therapy Tempe: are blood or marrow shots an option?

Why does the joint feel sore now?

Arthritis often makes a knee or hip stiff after sitting. An old injury can ache as activity increases, while a shoulder may hurt during reaching or at night. Swelling, weakness, and reduced motion add useful information.

Write down which activity starts your ache and when it begins. Check whether rest settles it by morning, then note any catching, swelling, or sudden weakness. Your notes give the doctor or nurse a solid place to begin.

What can you try at home?

Cut back on the motion that caused your soreness, but don't stop all movement unless a doctor ordered rest. Several brief walks may feel better than one hard outing. Light strength work can support the muscles around the joint.

Try a cold pack for new swelling, while heat may make stiffness easier to move. You may walk more steadily with a cane or the right brace. Before taking medicine, ask a doctor which choices fit your health needs.

When is it worth getting looked at?

Book an exam if soreness keeps limiting how you move each day. Tell the doctor or nurse when it began and name the motions that worsen it. Strength, movement, swelling, and sore areas are checked; an X-ray can show more when arthritis or an old injury is suspected.

Get care now for a fever along with one swollen joint that feels hot. Sudden weakness, numbness, or an injured leg that can't support you also needs prompt help. Those signs can mean more than ordinary wear and need quick attention.

Sources

1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

2. On 18 December 2024 FDA approved RYONCIL (remestemcel-L-rknd), the first mesenchymal stromal cell therapy ever approved in the United States - for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months and older, given as eight intravenous infusions. It is not an orthopedic product and does not make any joint injection approved.

   US Food and Drug Administration — FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease. , 2024.

3. On 27 September 2024 the Ninth Circuit held in United States v. California Stem Cell Treatment Center that stromal vascular fraction produced by enzymatically digesting a patient's own fat IS a drug under the Federal Food, Drug, and Cosmetic Act, and that the same surgical procedure exception does not apply because the removed fat and the implanted SVF are not the same thing. The district court's ruling for the clinics was reversed.

   United States Court of Appeals for the Ninth Circuit — United States v. California Stem Cell Treatment Center, Inc., No. 22-56014 (9th Cir. Sept. 27, 2024). , 2024.

4. A 2025 systematic review and meta-analysis of 8 randomized trials in 502 patients found intra-articular mesenchymal stem cells improved WOMAC scores versus control at 6 months (MD 7.44, 95% CI 1.45-13.42) and 12 months (MD 10.31, 95% CI 0.96-19.67), with wide confidence intervals and a small pooled sample.

   Cao M, et al. — Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2025. DOI: 10.1186/s13287-025-04252-2.

5. A 2025 systematic review and meta-analysis of 6 randomized trials found microfragmented adipose tissue and PRP both reached the minimal clinically important difference on most outcomes to 12 months, with no clear superiority of the fat-derived preparation despite its higher price.

   Park YB, et al. — Microfragmented Adipose Tissue as an Alternative to Platelet-Rich Plasma for Intra-articular Injection in Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Sports Med, 2025. DOI: 10.1177/03635465251337759.

6. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

7. In orders issued 26 December 2024 and announced 8 January 2025, a federal court permanently banned the co-founders of the Stem Cell Institute of America and their companies from marketing any regenerative medicine treatment, and ordered $5,155,146 in refunds and civil penalties. The court found on summary judgment that they published false and misleading advertisements about the efficacy and approval of stem cell injections for osteoarthritis, neuropathy and joint pain; their clinic charged up to $5,000 per injection and the customers were almost exclusively elderly and disabled people.

   US Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. , 2025.

8. A double-blind placebo-controlled trial of allogeneic culture-expanded adipose MSCs in stage III knee osteoarthritis kept blinding for 12 months and followed the treatment arm to 60 months, reporting only mild transient adverse events - but only 29 subjects completed, 8 of them in the placebo arm.

   Jafar H, et al. — Intra-articular allogeneic adipose-derived mesenchymal stromal cell injections for stage III knee osteoarthritis: a double-blind placebo-controlled trial with 60-month follow-up. Stem Cells Transl Med, 2026. DOI: 10.1093/stcltm/szag018.